ClinicalTrials.gg

Program

BLU-808

A development code.

In Sanofi's pipeline, Wild-type KIT inhibitor. Its studies are mostly in Chronic Urticaria, led by Sanofi.

Furthest: phase 2, since Apr 3, 20253 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi31 open or runningphase 2since Apr 3, 2025Apr 3, 2025Dec 31, 2026phase 2 · NCT06931405
  • Named in Sanofi’s own pipeline as SAR449028, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2025First studies: 2 phase 2 studiesFirst studyNCT06922448, NCT06931405
  2. Apr 22, 2025Phase 1 study in Healthy ParticipantsNCT06948032 · 95 enrolled · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Chronic Inducible UrticariaNCT06931405

TargetBeta

“Wild-type KIT inhibitor”the company's pipeline, read by Claude · source
“This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).”study summary, read by Claude · the study

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
velzatinibGlaxoSmithKlinephase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
elenestinibSanofiphase 33
NB-003ruleningbo-newbay-technology-development-co-ltdphase 32
briquilimabrulejasper-therapeutics-incphase 27

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06948032Healthy Participants · United States1CompletedJan 21, 202595
NCT06931405Chronic Inducible Urticaria · United States, Denmark, Germany and more2Active, not recruitingDec 31, 2026105
NCT06922448Allergic Rhinoconjunctivitis · Canada2CompletedSep 8, 202521

How it is read

Names in the registry

  • “BLU-808”, 3 entries

Codes read as this program: BLU808.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.